DT&CRO Co

DT&CRO Co Net Debt / EBITDA

The Net Debt to EBITDA of DT&CRO Co (383930.KQ) as of Oct 16, 2026 is -2.12. In the previous year, Net Debt to EBITDA was 1.33 — a change of -259.81% (lower).

Net Debt / EBITDA

-2.12

YoY

-259.81%

Last updated:

Net Debt to EBITDA of DT&CRO Co is 2024 -2.12 . Net Debt to EBITDA of DT&CRO Co was 2023 1.33 . It decreases by -259.81% lower compared to the previous year.

The DT&CRO Co Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2019
15.87 KRW
Jan 1, 2020
2.37 KRW
Jan 1, 2022
1.33 KRW
Jan 1, 2024
-2.12 KRW
The DT&CRO Co Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
-2.12-259.81%
1.33-43.92%
2.37-85.09%
15.87—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DT&CRO Co Stock analysis

What does DT&CRO Co do? DT&CRO Co Ltd is a South Korean company operating in the Health Care sector, specifically within the Life Sciences Tools & Services industry. Based in Yongin, the company has 277 employees and completed its initial public offering (IPO) on November 11, 2022. DT&CRO Co Ltd provides non-clinical and clinical trial services for pharmaceuticals, medical devices, food, chemicals, and cosmetics. The company also offers analysis, efficacy evaluation, and related services. Its headquarters are located in Yongin, Gyeonggi-Do, South Korea. The company's website is www.dtncro.com. DT&CRO Co Ltd is engaged in research and development activities related to medicine and pharmaceuticals, though specific details about its R&D focus or product offerings are not provided in the available information. The company operates as a service provider in the life sciences sector, supporting various industries through trial services and analytical solutions. As a publicly traded company, it is listed under the ticker symbol 383930.KQ with ISIN KR7383930005. The company's operations are centered on delivering specialized services to clients in the pharmaceutical and related industries, emphasizing both non-clinical and clinical trial support. DT&CRO Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DT&CRO Co stock

Net Debt to EBITDA of DT&CRO Co is -2.12 in 2024.

Net Debt to EBITDA of DT&CRO Co changed from 1.33 to -2.12, representing a -259.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA DT&CRO Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's DT&CRO Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — DT&CRO Co

All Key Metrics — DT&CRO Co